Sign In
Buy MRVSY
$3.15
-0.0600 (-1.87%)
At Close: Jun 03, 2026
MINERVA FOODS REPORTS CONSOLIDATED GROSS REVENUE OF R$ 6,8 BILLION IN THE FIRST QUARTER OF 2023
06:28pm, Tuesday, 09'th May 2023
EBITDA was R$ 531,9 million, and net revenue was R$ 6,4 billion SAO PAULO, May 9, 2023 /PRNewswire/ — Minerva Foods (Minerva S.A. – B3: BEEF3 | OTC – Nasdaq International: MRVSY), a leader in th
Minerva Announces Closing of Sale of Geology Division
08:00am, Friday, 09'th Dec 2022
VANCOUVER, BC , Dec. 9, 2022 /PRNewswire/ - Minerva Intelligence Inc. (TSXV: MVAI) (OTCQB: MVAIF) ("Minerva" or the "Company"), an artificial intelligence software company focused on building decisio
Minerva to Focus on Climate Risk Platform climate85 and Announces Sale of Geology Division
08:30am, Monday, 05'th Dec 2022
VANCOUVER, BC , Dec. 5, 2022 /PRNewswire/ - Minerva Intelligence Inc. (TSXV: MVAI) (OTCQB: MVAIF) ("Minerva" or the "Company"), an artificial intelligence software company focused on building decision
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
10:50am, Tuesday, 19'th Jan 2021
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus
H.C. Wainwright Thinks Minerva Neurosciences' Stock is Going to Recover - Markets
10:07am, Thursday, 02'nd Jul 2020
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Minerva Neurosciences (NERV – Research
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
02:31pm, Friday, 29'th May 2020
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms...
Minerva Neurosciences' stock plummets after schizophrenia treatment disappoints in phase 3 study
02:15pm, Friday, 29'th May 2020
Shares of Minerva Neurosciences Inc. plummeted 67% toward a 7-month low in morning trading Friday, enough to pace all Nasdaq losers, after the biopharmaceutical company announced disappointing result
